Health Products Act Penalties: Sections 14, 15 and 16

1. Key takeaways

Singapore’s Health Products Act attaches criminal penalties to three core offences: Section 14 — wholesale supply without a wholesaler’s licence, up to a fine of 50,000 Singapore dollars or imprisonment for up to 2 years, or both; Section 15 — supplying unregistered health products, up to a fine of 50,000 Singapore dollars or imprisonment for up to 2 years, or both; Section 16 — supplying adulterated, counterfeit, tampered or unwholesome health products, up to 50,000 Singapore dollars / 2 years or up to 100,000 Singapore dollars / 3 years depending on the offence. HSA’s enforcement practice shows sustained and intensifying action against online illegal sales and unregistered products.

• Registration under Section 15 is a precondition of supply, not merely a marketing requirement.
• Storage premises outside the licensed scope fall under Section 14(2).
• Counterfeit and adulterated products carry double the penalties of unwholesome products.
• A due-diligence defence exists under Section 16(3), but it must be built on documents.

2. Legal basis

The following table summarises the offences and penalties under the Health Products Act 2007 (Act No. 15 of 2007), Sections 14 to 16.

Defence under Section 16(3): the accused must prove that he did not know and had no reason to suspect the facts, could not with reasonable diligence have discovered them, and took all reasonable precautions and exercised all due diligence.

3. Expert insights

Five points explain how these criminal provisions bite in practice.

Insight 1: Section 15 makes registration a precondition of supply, not just a marketing threshold. The provision reads: except in such cases as may be prescribed, no person shall supply any health product unless the health product is a registered health product. This means that supplying without registration (or an applicable exemption completed through product notification) is an offence, regardless of whether the product itself is safe. This conflicts directly with the common habit of selling first and sorting out the paperwork slowly.

Insight 2: the storage premises provision in Section 14(2) is often overlooked. Changing warehouses or adding third-party logistics points without updating the licence falls squarely within that provision. When optimising regional warehousing and distribution, this is an easy line to cross. Every physical storage location must be checked against the licensed premises list before the first pallet arrives, and licence updates should be treated as a standing item in any logistics change plan rather than an afterthought once the move has already happened.

Insight 3: Section 16 doubles the penalties for counterfeit and adulterated products, reflecting enforcement priorities. Adulterated, counterfeit and tampered products: up to 100,000 Singapore dollars / 3 years. Unwholesome products: up to 50,000 Singapore dollars / 2 years. The legislative intent behind the difference is clear: offences involving greater subjective culpability are punished more severely.

Insight 4: HSA enforcement is substantive, not paper-based. Among the enforcement cases published by HSA are large-scale operations against illegal online sales (including the takedown of thousands of listings and the seizure of tens of thousands of illegal health products) and prosecutions of the offenders. In published cases, individuals were jailed for selling unregistered products via social media, and others were fined for performing aesthetic procedures without a licence and selling unregistered products. HSA has stated expressly that it takes a serious view of such conduct.

Insight 5: the compliance defence depends on written evidence, not on claiming ignorance. The Section 16(3) defence requires the accused to prove that the facts could not be discovered with reasonable diligence and that reasonable precautions were taken. In effect this demands a demonstrable compliance system in documents — supplier audits, incoming checks and licence verification records. Without documents, the defence of ignorance does not stand. In our experience the records that decide such cases are rarely dramatic: they are the routine incoming inspection sheets, the supplier qualification files and the dated licence checks that either exist or do not.

4. Practical recommendations

The following measures keep supply activities on the right side of Sections 14, 15 and 16.

1. Register first, supply later: Section 15 leaves no grey zone.
2. Ensure licences cover every activity: import, wholesale, export, manufacture and storage.
3. Build supplier and product compliance verification records: this is the evidentiary basis of the due-diligence defence.
4. Pay special attention to online channels: social media and e-commerce are HSA’s priority enforcement areas.
5. Run periodic compliance health checks: self-assess line by line against Sections 14, 15 and 16.

Regulatory information verified as of: 26 October 2026

Source level: Tier 1 (Health Products Act 2007, Sections 14, 15 and 16), Tier 2 (official HSA enforcement announcements)

5. Verification checklist

• □ All products on sale are registered or product-notified (Section 15)
• □ Wholesale activities are conducted under a valid wholesaler’s licence (Section 14)
• □ Storage premises are within the licensed scope (Section 14(2))
• □ Supplier and product compliance verification records are complete and producible
• □ Online and social media promotional content has passed compliance review
• □ Periodic self-checks against Sections 14, 15 and 16 are in place

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com